Antihypertensive Effects of Drospirenone With 17&bgr;-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension

  title={Antihypertensive Effects of Drospirenone With 17\&bgr;-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension},
  author={William B. White and Bertram Pitt and Richard A. Preston and Vladimir Hanes},
Background—Drospirenone (DRSP) is a novel progestin with antimineralocorticoid activity that has been developed for hormone therapy in combination with 17&bgr;-estradiol (E2) in postmenopausal women. In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP). Methods and Results—The effects of 3 mg DRSP/1 mg E2 on clinic and 24-hour ambulatory BP as well as potassium homeostasis were… 

Figures and Tables from this paper

Effects of a New Hormone Therapy, Drospirenone and 17-&bgr;-Estradiol, in Postmenopausal Women With Hypertension

Data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium, which may lead to a new benefit for this novel hormone therapy in postwomen's hypertension.

Analysis of Recent Papers in Hypertension

Using an intention-to-treat analysis, treatment with DRSP-E2 led to significantly greater reductions in clinic systolic BP by 2 weeks and diastolic BPBy 4 weeks.

Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide

DRSP/E2 substantially lowers systolic and diastolic blood pressure when added to existing antihypertensive therapy with HCTZ in hypertensive postmenopausal women and has a potassium-sparing effect that counteracts HCTz-induced potassium loss.

Clinical and metabolic effects of drospirenone–estradiol in menopausal women: a prospective study

In postmenopausal women, E2++DRSP administration improves vasomotor symptoms and general aspects of quality of life and may positively influence cardiovascular risk factors.

Pharmacokinetics and Pharmacodynamics of Drospirenone‐Estradiol Combination Hormone Therapy Product Coadministered With Hydrochlorothiazide in Hypertensive Postmenopausal Women

Results showed that the combination of DRSP/E2 plus 25 mg of HCTZ is safe and well tolerated in hypertensive postmenopausal women.

Drospirenone, a New Progestogen, for Postmenopausal Women with Hypertension

Drospirenone is a unique progestogen that confers the additional benefit of BP reduction, an effect that could lead to potential benefit with respect to some cardiovascular risk concerns in women taking hormone therapy.

Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women.

The oral HRT of 1 mg E2 plus 2 mg DRSP was effective and well tolerated by Thai women suffering from postmenopausal symptoms and the frequency of hot flushes was reduced.

Advances in hormone replacement therapy: Weight benefits of drospirenone, a 17α-spirolactone-derived progestogen

  • J. FoidartT. Faustmann
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2007
E2/DRSP could help maintain or even slightly decrease body weight during treatment, potentially improving HRT acceptance and compliance and reducing estrogen-related sodium and water retention in postmenopausal women receiving HRT.



Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.

To the authors' knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure and may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure.

Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension

Eplerenone was as effective as amlodipine in lowering systolic BP and pulse pressure as well as pulse wave velocity in older patients with widened pulse pressure hypertension and reduced microalbuminuria to a greater extent in this older patient group.

Estrogen plus progestin and the risk of coronary heart disease.

Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use.

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.

Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Observations indicate a vascular and end organ protective effect of spironolactone in the absence of lowered blood pressure in saline-drinking stroke-prone spontaneously hypertensive rats and are consistent with a major role for mineralocorticoids as hormonal mediators of vascular injury.